Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asundexian - Bayer Healthcare

X
Drug Profile

Asundexian - Bayer Healthcare

Alternative Names: BAY-2433334

Latest Information Update: 14 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class Amides; Anticoagulants; Antithrombotics; Chlorobenzenes; Ethers; Fluorobenzenes; Pyridines; Small molecules; Triazoles; Vascular disorder therapies
  • Mechanism of Action Factor XIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atrial fibrillation; Stroke; Thromboembolism

Most Recent Events

  • 13 Dec 2023 Bayer terminates phase III OCEANIC-AF trial due to an inferior efficacy in Stroke (Prevention) in China, Australia, Argentina, Austria, Brazil, Bulgaria, Canada, Croatia, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, New Zealand, South Korea, Latvia, Lithuania, Malaysia, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, UK (PO)
  • 13 Dec 2023 Bayer terminates phase III OCEANIC-AF trial due to an inferior efficacy in Thromboembolism (Prevention) (with atrial fibrillation) in India, Italy, Kazakhstan, Portugal, Turkey, China, Australia, Argentina, Austria, Brazil, Bulgaria, Canada, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Malaysia, Netherlands, Norway, Poland, Portugal, Romania, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey, UK (PO)
  • 10 Nov 2023 Phase-III clinical trials in Atrial fibrillation (In the elderly) (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top